Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

XtalPi Holdings Limited
晶泰控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2228)

VOLUNTARY ANNOUNCEMENT

AI-DRIVEN DRUG DISCOVERY COLLABORATION BETWEEN XTALPI AND LABORATOIRES PIERRE FABRE

This announcement is made by XtalPi Holdings Limited (the "**Company**" or "**XtalPi**", together with its subsidiaries, the "**Group**") on a voluntary basis. The purpose of this announcement is to keep the shareholders and potential investors of the Company informed of the latest business development of the Group.

The board of directors of the Company (the "**Board**") is pleased to announce that QuantumPharm Limited and Jingtai Zhiyao Technology (Shanghai) Co., Ltd. (晶泰智藥技術(上海)有限公司), each a wholly-owned subsidiary of the Company, and Pierre Fabre Médicament SAS, a member of the Laboratoires Pierre Fabre group ("**Laboratoires Pierre Fabre**"), have entered into a research collaboration agreement (the "**Collaboration**") under which the Group and Laboratoires Pierre Fabre will collaborate on the discovery of novel clinical candidates across a number of research programs in the field of oncology, and potentially dermatology and rare diseases.

Under the Collaboration, the Group will use its integrated AI capabilities and robotics platform to de novo design and deliver novel small molecule therapeutics against undisclosed targets. Laboratoires Pierre Fabre will contribute its expertise in disease biology, discovery, translational research and clinical development to select and advance the most promising compounds, and will be responsible for subsequent clinical and commercial development.

The Collaboration reflects the parties' shared interest in exploring challenging and historically hard-to-drug targets, an area associated with significant unmet medical need and substantial opportunity in innovative drug discovery. Together, the parties aim to accelerate the identification of high-quality clinical candidates across multiple research programs in oncology and potentially other therapeutic areas.

The Collaboration includes an upfront payment, multiple milestone payments and downstream economic participation.

The Board considers that the Collaboration advances the Group's efforts to apply AI and robotics to de novo drug discovery, reinforces the Group's position in AI- and robotics-powered drug discovery, and is in the interests of the Company and its shareholders as a whole.

About Laboratoires Pierre Fabre

Laboratoires Pierre Fabre is one of Europe's leading pharmaceutical laboratories and the world's second-largest dermo-cosmetics company. Its Pharma activity covers 5 main therapeutic fields: oncology, dermatology, rare diseases, primary care and family health care. For over 40 years, Laboratoires Pierre Fabre has established itself as an international player in oncology, mastering the entire value chain from R&D to marketing. In 2025, Laboratoires Pierre Fabre's total sales amounted to 3.2 billion euros and its R&D budget amounted to 250 million euros. Based in southwest France since its creation, Laboratoires Pierre Fabre employs 10,000 people worldwide, and its majority shareholder (86%) is an eponymous humanitarian foundation.

About XtalPi

XtalPi was founded in 2015 by three physicists from the Massachusetts Institute of Technology (MIT). It is an innovative R&D platform powered by quantum physics, artificial intelligence, and robotics. By integrating first-principles calculations, AI algorithms, high-performance cloud computing, and standardized automation systems, XtalPi provides digital and intelligent R&D solutions for companies in the pharmaceutical, materials science, agricultural technology, energy, new chemicals, and cosmetics industries.

By Order of the Board
XtalPi Holdings Limited
Dr. Wen Shuhao
Chairman of the Board and Executive Director

Hong Kong, 9 November 2026

As at the date of this announcement, the Board comprises Dr. Wen Shuhao, Dr. Ma Jian, Dr. Lai Lipeng and Dr. Jiang Yide Alan as executive directors, and Mr. Law Cheuk Kin Stephen, Ms. Chan Wing Ki and Mr. Chow Ming Sang as independent non-executive directors.